International Congress of Parkinson's Disease and Movement Disorders

The TOLEDO study noted it also increased “on” time without troublesome dyskinesia.

No evidence of adverse events or significant safety concerns has surfaced.

The development was presented by David Eidelberg, MD, at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Scores on key scales improved 20%–28% after 1 year of jejunal levodopa/carbidopa.

Patient- and clinician-rated outcomes were keys in supporting labeling claims.

The method alleviates the 2 drugs' strained efficacy over time during Parkinson's progression.

RT002 could treat moderate to severe isolated cervical dystonia with 2 or fewer annual shots.

Samuel Frank, MD, director of the Huntington's Disease Society America Centers of Excellence at the Beth Israel Deaconness Medical Center, discusses hitting the moving target of Huntington's treatment, and his research on deutetrabenazine for the rare disease.

Investigational levodopa form CVT-301 improves "off" period motor function.

A disease that affects the motor and cognitive system can be treated well by physical therapy and exercise, Daniel M. Corcos, PhD, said.

Daniel M. Corcos, PhD, discusses the value of routine balance intervention activities for Parkinson's disease patients at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Aleksandar Videnovic, MD, associate professor at the Massachusetts General Hospital, discusses new patient monitoring opportunities and other methods of treatment for one of Parkinson's disease patients' most common symptoms.

BMS-986168 significantly reduces CSF free eTau.

A Phase II-B trial with early to moderate PD patients showed efficacy.

An Italian team presented its research on the topic at the 2017 International Congress of Parkinson’s Disease & Movement Disorders Conference.

Anthony Lang, MD, FRCPC, professor and director of the Division of Neurology at the University of Toronto, discusses the potentially comprehensive care of investigational disease modifying treatment PRX002,

The study gauged elderly Parkinson's patients over a 5-year span.

Psychosis and dementia are major risk factors for Parkinson's patients.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

An expert offers insights on levodopa-induced motor complications in Parkinson’s disease.

Norika Malhado-Chang, MD, assistant professor of Neurology at University of California at Davis, discusses how progress in Parkinson's disease and movement disorders is changing the scope of comprehensive care, addressing non-motor symptoms, and supplying tools for the next generation of neurology specialists.

A study has found an alternative motor treatment from levodopa.

The first step in successfully treating chorea is making the correct diagnosis.

Specific dystonia cases require specific treatments.

Researchers were able to pull 25,000 hours of monitoring data.

"We have some major changes in the way we treat Parkinson's."